I think that's a potential, yes. There are economies of scale. We're just in the process right now of gearing up our production facility. Of course, our cost of production to date is calculated on what our production yields have been. We're not manufacturing 50 million doses per year or enough for $59 of sales. I think it's a very fair question. Yes, it could go down.
More importantly, should any licensed E. coli vaccine come on the market, I wouldn't expect any government program to mandate one specific vaccine. Any one of those could be used. What I'm getting at is that with competition comes pressure on price. I also know that technology-wise, we're now looking at potentially second- and third- generation vaccines. Part of their appeal is they're going to have lower costs of production, so I think it's fair to expect that the cost would ultimately come down.